X0206 3 2018-06-20 0 0001346302 XERIS PHARMACEUTICALS INC XERS 0001553595 Shannon John Patrick Jr C/O XERIS PHARMACEUTICALS, INC. 180 N. LASALLE STREET, SUITE 1810 CHICAGO IL 60601 0 1 0 0 See Remarks Stock Option (Right to Buy) 1.55 2027-02-03 Common Stock 160335 D Stock Option (Right to Buy) 1.55 2027-06-11 Common Stock 25136 D Stock Option (Right to Buy) 5.93 2028-01-31 Common Stock 28072 D Stock Option 12.50 2028-05-15 Common Stock 34977 D Series C Preferred Stock Common Stock 8983 D 25% of these shares shall vest on the first anniversary of the vesting commencement date, with the remainder vesting ratably over 36 months. Each share of preferred stock is convertible on a 1.78112-for-1 basis into Common Stock at any time at the election of the Reporting Person and will automatically convert upon the closing of the Issuer's initial public offering into the number of shares of the Issuer's Common Stock shown in column 3 without payment or further consideration. The shares have no expiration date. Executive Vice President and Chief Operating Officer Exhibit 24 - Power of Attorney /s/ Barry Deutsch, as Attorney-in-Fact 2018-06-20